Company Subsidiary HempMeds® to Sponsor and Exhibit at Expo; Mexico Activist Raul Elizalde Joins Lawmakers at Expo to Discuss Latin America’s Evolving Cannabis Policy
SAN DIEGO, June 7, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its Chief Executive Officer Dr. Stuart Titus will be delivering a keynote speech on “The Exploding Marketplace of Cannabidiol (CBD)” at Florida’s first Southeast Cannabis Conference & Expo on June 11. Medical Marijuana, Inc. subsidiary HempMeds® will also be sponsoring and exhibiting its line of CBD hemp oil products at the Expo.
A first of its kind event since the passage of Amendment 2 in Florida, this cannabis conference brings together experts from the local, regional and national cannabis industry. The Southeast Cannabis Conference & Expo, taking place in Fort Lauderdale, Fla., from June 9-11, 2017, will focus on the potential transitions and changes coming to marijuana and cannabis policy in 2017 and 2018.
As part of his keynote address on Sunday, June 11, from 11:00-11:45 a.m., Dr. Titus will discuss the history of hemp in America and its applications in modern day medicine. In addition, medical cannabis activist Raul Elizalde of Mexico will join Company representatives and Mexico Senator Cristina Diaz Salazar, who introduced medical marijuana legislation in Mexico, on a Changes in Mexico Marijuana Policy panel on Saturday, June 10, from 3:00-3:45 p.m.
“I am honored to be speaking about cannabinoid science at Florida’s first cannabis conference to be held in the state since the passage of Amendment 2, Florida’s Medical Marijuana Legalization Initiative, which was approved by more than 71 percent of Florida voters this past November,” Titus said. “The topic of medical cannabis policy that this Expo will address is now more critical than ever as lawmakers in the U.S. and across the globe are making decisions that can affect the fate of cannabis reform. Our goal is to continue fighting for responsible medical cannabis policy and to bring attention to the need for and protection of medical marijuana policies that can save lives.”
Elizalde, who has been publicly thanked by Mexico President Enrique Pena Nieto for his efforts to help pass a bill that authorizes the use of drugs made from cannabis, will discuss how his efforts have provided the people of Mexico access to hemp CBD products such as Real Scientific Hemp Oil-X™ (RSHO-X™), a product of Medical Marijuana, Inc. subsidiary HempMeds® and the first-ever cannabis product approved for import by the federal government of Mexico.
Additionally, visitors who stop by the HempMeds® booth #609 can expect to learn more about the Company’s unique line of CBD hemp oil supplements, including its award-winning brands like Dixie Botanicals® and Real Scientific Hemp Oil™ (RSHO™). As the first nationally distributed cannabis company, HempMeds® locally made products can be accessed by anyone in the United States without a doctor’s prescription, regardless of where they live.
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company, handling sales and distribution.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.